Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Hao Chen

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5134173076. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
38
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: 3 papers · 2019: 1 paper · 2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 2 papers

Papers 12

  1. Lactate-associated gene PLAU promotes liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.compbiolchem.2026.109075↗
  2. Targeting CYBA inhibits hepatic metastasis of pancreatic cancer through AKT/MLC2 pathway. Co-author DOI 10.1038/s41401-026-01880-z↗
  3. Immunosenescence-Related Gene MAFF is Involved in Immune Regulation and Malignant Progression in Pancreatic Adenocarcinoma. Last author DOI 10.1186/s12575-025-00278-1↗
  4. Digital subtraction angiography-guided pancreatic arterial infusion of GEMOX chemotherapy in advanced pancreatic adenocarcinoma: a phase II, open-label, random… Co-author DOI 10.1186/s12885-024-12695-8↗
  5. Elastic modulus-reflected liver lesion stiffness relates to worse prognosis in pancreatic cancer patients with liver metastasis. Last author DOI 10.1186/s12957-023-03140-4↗
  6. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression. Co-author DOI 10.18632/aging.102638↗
  7. Albumin-to-alkaline phosphatase ratio serves as a prognostic indicator in unresectable pancreatic ductal adenocarcinoma: a propensity score matching analysis Co-author DOI 10.21203/rs.2.24244/v1↗
  8. ARHGAP4 regulates the cell migration and invasion of pancreatic cancer by the HDAC2/β-catenin signaling pathway. Co-author DOI 10.1093/carcin/bgz067↗
  9. CBX3 promotes proliferation and regulates glycolysis via suppressing FBP1 in pancreatic cancer. Co-author DOI 10.1016/j.bbrc.2018.04.137↗
  10. Natural Compound Methyl Protodioscin Suppresses Proliferation and Inhibits Glycolysis in Pancreatic Cancer. Co-author DOI 10.1155/2018/7343090↗
  11. Prognostic values of common clinical parameters in advanced pancreatic ductal adenocarcinoma: a large multicenter cohort study of ten years. Co-author PMID 29641971↗
  12. High expression of erythropoietin-producing hepatoma cell line-B2 (EphB2) predicts the efficiency of the Qingyihuaji formula treatment in pancreatic cancer CFP… Co-author DOI 10.3892/ol.2014.2134↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jiangang Zhao · 3 shared papers, 2025–2026 · strength 0.87
  2. Zhen Chen · 6 shared papers, 2014–2024 · strength 0.64
  3. Xinghe Liao · 2 shared papers, 2025–2026 · strength 0.60
  4. Chien‐shan Cheng · 4 shared papers, 2018–2024 · strength 0.48
  5. Yehua Shen · 4 shared papers, 2014–2024 · strength 0.42
  6. Shu Dong · 3 shared papers, 2018–2023 · strength 0.40
  7. Lianyu Chen · 4 shared papers, 2018–2020 · strength 0.40
  8. Zhiqiang Meng · 4 shared papers, 2018–2020 · strength 0.36
  9. Yongqiang Hua · 3 shared papers, 2014–2024 · strength 0.36
  10. Ping Li · 1 shared paper, 2026 · strength 0.32
  11. zhou zhou · 1 shared paper, 2026 · strength 0.32
  12. Huifeng Gao · 3 shared papers, 2018–2020 · strength 0.31
  13. Fenglin Zhang · 1 shared paper, 2025 · strength 0.28
  14. Haibo Cheng · 1 shared paper, 2026 · strength 0.27
  15. Hao-jie Du · 1 shared paper, 2026 · strength 0.27
  16. Xian Miao · 1 shared paper, 2023 · strength 0.22
  17. Xiaoyan Zhu · 1 shared paper, 2023 · strength 0.22
  18. Changjing Huang · 1 shared paper, 2024 · strength 0.20
  19. Lanyun Feng · 1 shared paper, 2024 · strength 0.20
  20. Peng Wang · 1 shared paper, 2024 · strength 0.20
  21. Zhiqiang Meng · 1 shared paper, 2024 · strength 0.20
  22. Luming Liu · 2 shared papers, 2018–2019 · strength 0.18
  23. Chao Qu · 2 shared papers, 2018 · strength 0.16
  24. Yanhua Jing · 1 shared paper, 2020 · strength 0.12
  25. Ke Zhang · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.